Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate-to-severe atopic dermatitis. Sold as Ebglyss. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Lebrikizumab-Lbkz (sold as Ebglyss), first approved Sep 13, 2024, with 1 new use approved and 1 published complete response letter.
First approved: Sep 13, 2024
Applications: 1
New uses approved: 1
Complete response letters: 1
Medicare spending, 2025: $95.9M
First approved in the EU: Nov 16, 2023
First approved in Japan: Jan 18, 2024
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 8 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Ebglyss, new ingredientDrugs with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. · Eli Lilly Japan K.K. · Jan 18, 2024 · Review report
Clinical Trials
1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA